Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
34.24 USD | -4.09% | -3.82% | +34.49% |
Financials (USD)
Sales 2024 * | 50.98M | Sales 2025 * | 70.78M | Capitalization | 2.19B |
---|---|---|---|---|---|
Net income 2024 * | -206M | Net income 2025 * | -240M | EV / Sales 2024 * | 35.5 x |
Net cash position 2024 * | 380M | Net cash position 2025 * | 373M | EV / Sales 2025 * | 25.7 x |
P/E ratio 2024 * |
-12.3
x | P/E ratio 2025 * |
-10.9
x | Employees | 186 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.75% |
Latest transcript on Kymera Therapeutics, Inc.
1 day | -4.09% | ||
1 week | -3.82% | ||
Current month | +1.84% | ||
1 month | -4.12% | ||
3 months | -18.16% | ||
6 months | +71.63% | ||
Current year | +34.49% |
Managers | Title | Age | Since |
---|---|---|---|
Nello Mainolfi
FOU | Founder | 45 | 15-08-31 |
Bruce Jacobs
DFI | Director of Finance/CFO | 54 | 19-07-14 |
Juliet Williams
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Felix Baker
BRD | Director/Board Member | 55 | Mar. 27 |
Joanna Horobin
BRD | Director/Board Member | 69 | 18-04-30 |
John Maraganore
BRD | Director/Board Member | 60 | 22-01-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.05% | 1,487 M€ | +8.16% | - | |
0.04% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 34.24 | -4.09% | 495 952 |
24-05-22 | 35.7 | +1.08% | 515,262 |
24-05-21 | 35.32 | -1.92% | 431,107 |
24-05-20 | 36.01 | +3.03% | 378,761 |
24-05-17 | 34.95 | -1.83% | 493,095 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.49% | 2.19B | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- KYMR Stock